Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
-
HRSA Revises RWHAP Policy Notice on Eligibility Determinations
In October 2021, HRSA's HIV/AIDS Bureau revised its client eligibility and recertification policy for the Ryan White HIV/AIDS Program.
News Article updated on 11/02/2021 -
HRSA Releases New Fact Sheets on RWHAP Clients
Ten fact sheets on client populations getting care from the Ryan White HIV/AIDS Program (RWHAP) a
News Article updated on 06/30/2021 -
Use of Social Media and Mobile Technology as Essential Tools for EHE
Strategies to engage hard-to-reach youth and young adults through use of social media and related technologies.Resource updated 03/15/2023
-
Online Course on Integrated Planning
-
Identifying and Incorporating into Practice Screening Tools for People with HIV who are Aging in the Ryan White HIV/AIDS Program
This HRSA HIV/AIDS Bureau national webinar featured two Ryan White HIV/AIDS Program (RWHAP) providers.
Resource updated 06/09/2022
-
Ending the HIV Epidemic through Innovations in Rapid ART
Review of innovative Rapid ART strategies in diverse settings.Resource updated 03/15/2023
-
Medical Monitoring Project 2019-2020 Data on HIV Care Access and Health Outcomes
In the U.S., almost all people with HIV have some type of health insurance coverage (pub
News Article updated on 08/09/2021 -
Innovation and Resilience: How Ryan White HIV/AIDS Program Recipients Leverage Telehealth during the COVID-19 Pandemic
Recap of changes made in telehealth laws, regulations, and policies and corresponding efforts of healthcare systems, payers, and providers to modify their services to keep clients with HIV engaged in care provided by HRSA's Ryan White HIV/AIDS Program.Resource updated 06/09/2022
-
Reflections on COVID-19 Driven Telehealth Implementation in the RWHAP
The HRSA white page Innovation and Resilience: How Ryan White HIV/AIDS Program Recipients Leverage Telehealth during the COVID-19 Pandemic offers lessons for future service delivery.Blog updated 01/23/2023
-
New Investigational ART Drugs and Strategies
Review of investigational drugs in phase III trials (as of 2021: Islatravir, Lenacapravir, GSK 3640254/aka GSK “254) and how these investigational agents might be used in treatment in the future. Also, review of long-acting injectables.Resource (Conference Presentation) updated 09/14/2023
-
An Update on COVID-19
Review of COVID-19 risks in people with HIV (PWH), covering: risks; vaccination and prevention measures; and treatment considerations.Resource (Conference Presentation) updated 09/14/2023
-
40 Years of Progress: Looking Back at the Beginning of the HIV/AIDS Epidemic in the Bay Area
Moderated discussion (Saag, Cheever) of those that were involved at the very start of the HIV/AIDS epidemic in the San Francisco Bay Area.
Panelists: Kathleen A. Clanon, MD, Director, Alameda Care Connect; Marcus A. Conant, MD, Co-founder, San Francisco AIDS Foundation; Alison Moed, RN, Head Nurse, AIDS Ward, San Francisco General Hospital; Michael Reyes, MD, University of California San Francisco; Paul A. Volberding, MD, University of California San Francisco.
Resource (Conference Presentation) updated 09/14/2023
-
Managing Polypharmacy and Drug-Drug Interactions
Review of common mechanisms for drug interactions with contemporary ART; therapeutic classes of drugs with high interaction potential with ART; distinctions between oral vs intramuscular cabotegravir/rilpivirin interactions; and comparison of the clinical pharmacology and drug interaction potential of tenofovir alafenamide vs tenofovir disoproxilfumarate.Resource (Conference Presentation) updated 09/14/2023
-
Cases From the Clinic(ians): Antiretroviral Therapy Cases and Panel Discussion
Insights for clinicians on selecting antiretroviral therapy and/or managing patients who: are starting initial therapy; are Elite Controllers; have InSTI-associated weight gain; have persistent low-level viremia; have a discordant CD4+ count response to ART; have ‘Blips’; and/or are aging.Resource (Conference Presentation) updated 04/08/2024
-
Transgender Women Engagement and Entry to Care (T.W.E.E.T): E2i
T.W.E.E.T. aims to engage transgender women in HIV care by combining weekly peer-based education and discussion groups, leadership training, community building, and the provision of supportive services. Three sites implemented T.W.E.E.T. as part of E2i, an initiative funded by the RWHAP Part F SPNS program from 2017–2021. Clients had improved outcomes across the HIV care continuum 12 months after enrollment in T.W.E.E.T.Resource from the RWHAP Best Practices Compilation updated on 02/09/2024
-
Bilingual and Bicultural Care Team
Hispanic and Latino clients served by the team received culturally responsive care and linkages to external community resources, with resulting greater retention in care and improved viral suppression rates.Resource from the RWHAP Best Practices Compilation updated on 01/03/2024
-
FY23 RWHAP Part A Non-Competing Continuation Progress Report
FY2023 Ryan White HIV/AIDS Program (RWHAP) Part A Non-Competing Continuation Progress Report.Resource updated 09/19/2023
-
Integration of Oral Health and Primary Care in Seattle-King County
This referral-based oral health model used dental navigators to connect clients to a large network of dentists, which facilitated scheduling of appointments.Resource from the RWHAP Best Practices Compilation updated on 11/02/2023
-
Long-Acting Injectable ART: Coverage and Cost-Sharing Considerations
Review of fact sheet on different coverage and cost-sharing considerations for LAI ART across public and private payers.Blog updated 12/22/2022